-transparent.png){kind=logo}
Eighty-nine isolates of Neisseria gonorrhoeae from 89 male urethritis patients were studied for beta-lactamases (penicillinase) production, and their susceptibilities to benzylpenicillin, amoxicillin, piperacillin, clavulanic acid/amoxicillin (Augmentin), cephalexin, cefotaxime, spectinomycin and minocycline were determined by an agar plate-dilution method. Penicillinase activity was tested by a chromogenic cephalosporin method with nitrocefin as substrate (CefinaseTM discs, BBL, USA) and by a paper strip acidimetric method with benzylpenicillin as substrate (beta-Lactamase detection papers, Oxoid, UK). In addition, 60 of the 89 patients were examined for Chlamydia trachomatis, using fluorescein-labeled monoclonal antibodies (Direct specimen test; Micro TrakTM, Syva Co., USA). Penicillinase-producing N. gonorrhoeae (PPNG) were found in 12 of the 89 strains (13.5%). Although all these strains of PPNG were highly resistant to benzylpenicillin and amoxicillin, the minimum inhibitory concentrations (MICs) of Augmentin markedly decreased. Piperacillin was highly active against not only non-PPNG but also PPNG strains. More than half the isolates were resistant to cephalexin (MICs greater than or equal to 12.5 micrograms/ml) while all strains including non-PPNG and PPNG were fully sensitive to cefotaxime (MICs less than or equal to 0.20 microgram/ml). Spectinomycin and minocycline had MIC ranges of 6.25 to 25 micrograms/ml and 0.01 to 3.13 micrograms/ml, respectively; the ranges for non-PPNG and PPNG strains were fairly similar. C. trachomatis was detected in 11 (18.3%) out of 60 patients examined. The increasing incidence of PPNG and coexisting chlamydial infection should be taken into account in the treatment of gonococcal urethritis.
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
October 1982,
Medical laboratory sciences,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
January 1984,
Clinical therapeutics,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
August 1982,
British medical journal (Clinical research ed.),
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
October 1977,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
January 1987,
Indian journal of dermatology, venereology and leprology,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
February 1988,
The Western journal of medicine,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
October 1976,
Lancet (London, England),
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
March 1988,
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
January 1987,
Annales de dermatologie et de venereologie,
M Ohkawa, and
T Nakajima, and
S Tokunaga, and
S Kawaguchi, and
T Sugata, and
H Hisazumi, and
K Ueno, and
K Watanabe
December 1982,
The New England journal of medicine,
